PL1694709T3 - Rekombinowane anty-CD64 immunotoksyny z udziałem ETA - Google Patents

Rekombinowane anty-CD64 immunotoksyny z udziałem ETA

Info

Publication number
PL1694709T3
PL1694709T3 PL04819218T PL04819218T PL1694709T3 PL 1694709 T3 PL1694709 T3 PL 1694709T3 PL 04819218 T PL04819218 T PL 04819218T PL 04819218 T PL04819218 T PL 04819218T PL 1694709 T3 PL1694709 T3 PL 1694709T3
Authority
PL
Poland
Prior art keywords
vectors
diseases
further relates
complex
complex according
Prior art date
Application number
PL04819218T
Other languages
English (en)
Inventor
Michael Huhn
Rainer Fischer
Mehmet Kemal Tur
Theo Thepen
Stefan Barth
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Publication of PL1694709T3 publication Critical patent/PL1694709T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04819218T 2003-11-26 2004-11-25 Rekombinowane anty-CD64 immunotoksyny z udziałem ETA PL1694709T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027161 2003-11-26
EP04819218A EP1694709B1 (en) 2003-11-26 2004-11-25 Recombinant anti-cd64-eta' immunotoxins
PCT/EP2004/013374 WO2005052007A1 (en) 2003-11-26 2004-11-25 Recombinant anti-cd64-immunotoxins

Publications (1)

Publication Number Publication Date
PL1694709T3 true PL1694709T3 (pl) 2011-05-31

Family

ID=34626377

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04819218T PL1694709T3 (pl) 2003-11-26 2004-11-25 Rekombinowane anty-CD64 immunotoksyny z udziałem ETA

Country Status (8)

Country Link
EP (1) EP1694709B1 (pl)
AT (1) ATE491728T1 (pl)
DE (1) DE602004030617D1 (pl)
DK (1) DK1694709T3 (pl)
ES (1) ES2358022T3 (pl)
PL (1) PL1694709T3 (pl)
PT (1) PT1694709E (pl)
WO (1) WO2005052007A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008321026B2 (en) * 2007-11-13 2014-01-16 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
EP3231812B1 (en) * 2011-06-09 2020-03-25 The United States of America, as represented by the Secretary, Department of Health and Human Services Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes
PL2755993T3 (pl) 2011-09-16 2018-04-30 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Egzotoksyna A Pseudomonas z mniej immunogennymi epitopami komórek B
CN106456750A (zh) * 2014-03-26 2017-02-22 弗劳恩霍夫应用研究促进协会 CD‑64阻断剂作为抗TNF‑α抗体疗法的增强剂的用途
US20170369574A1 (en) 2015-01-21 2017-12-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. An immunotoxin for use in the treatment of leishmaniasis
WO2025128434A1 (en) 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia
CN118370830B (zh) * 2024-06-25 2024-10-11 中国人民解放军军事科学院军事医学研究院 与高亲和力受体Fcgr1相关的生物材料的应用及缓解辐射性骨损伤的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127141A1 (de) * 1998-11-07 2001-08-29 Stefan Barth Verfahren zur expression rekombinanter proteine unter ausnutzung der wirkung von stress und stressantwortmechanismen in gegenwart kompatibler solute
EP1283719B1 (de) * 2000-04-22 2007-09-05 PharmedArtis GmbH Apoptotika
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances

Also Published As

Publication number Publication date
PT1694709E (pt) 2011-03-17
EP1694709A1 (en) 2006-08-30
ES2358022T3 (es) 2011-05-04
ATE491728T1 (de) 2011-01-15
DE602004030617D1 (de) 2011-01-27
DK1694709T3 (da) 2011-04-04
WO2005052007A1 (en) 2005-06-09
EP1694709B1 (en) 2010-12-15

Similar Documents

Publication Publication Date Title
MX2011007582A (es) Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
EP1778842B8 (en) Compositions and methods of use for mgd-csf in disease treatment
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
WO2005086798A3 (en) Improved interleukin-2 muteins
WO2002102997A3 (en) Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
AU6912294A (en) Immunotoxins comprising ribosome-inactivating proteins
TNSN06059A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
PL1694709T3 (pl) Rekombinowane anty-CD64 immunotoksyny z udziałem ETA
NZ273258A (en) Immunomodulator composition with components less than 3000 D that are extractable from bile, stimulate monocytes and macrophages and modulate TNF
MX2025007855A (es) Proteina triespecifica dirigida a trop2 para el tratamiento del cancer
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
WO1999046371A3 (en) Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
AU6450098A (en) Butyrate prodrugs derived from lactic acid
Rowe et al. Hemopoietic growth factors: a review
AU2003260452A1 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
GR3035899T3 (en) Butyrate prodrugs of lactic acid
PL363501A1 (pl) Zmodyfikowany czynnik stymulujący kolonię granulocytów (G-CSF) o obniżonej immunogeniczności
JP2003521439A5 (pl)
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
WO2002079222A3 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
CA2460331A1 (en) Use of a protein for the production of a medicament for stimulating the innate non-specific immune system
WO2008038296A3 (en) Recombinant calcitonin fused to interleukin-2